We sought to identify immune cell types that significantly (two-sample t-tests; p < 0.05) differed in activity across breast cancer patient groups with high and low expression of RAD52 and PBX2 linked to their survival outcomes (Figure 8A,C). This evidence concerns the gene RAD52 and breast cancer.